There has been rapid growth in teledermatology over the past decade, and teledermatology services are increasingly being used to support patient care across a variety of care settings. Teledermatology has the potential to increase access to high-quality dermatologic care while maintaining clinical efficacy and cost-effectiveness. Recent expansions in telemedicine reimbursement from the Centers for Medicare & Medicaid Services (CMS) ensure that teledermatology will play an increasingly prominent role in patient care. Therefore, it is important that dermatologists be well informed of both the promises of teledermatology and the potential practice challenges a continuously evolving mode of care delivery brings. In this article, we will review the evidence on the clinical and cost-effectiveness of teledermatology and we will discuss system-level and practice-level barriers to successful teledermatology implementation as well as potential implications for dermatologists.Le texte complet de cet article est disponible en PDF.
Key words : teledermatology, store-and-forward, cost-effectiveness, barriers, reimbursement, medicolegal, health care costs
Abbreviations used : CMS, HIPAA
| Funding sources: Dr Barbieri is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number T32-AR-007465 and receives partial salary support through a Pfizer Fellowship grant to the Trustees of the University of Pennsylvania.
| Disclosure: Dr Stavert receives salary compensation as a part-time employee for Philips. Ms Wang and Drs Barbieri, Nguyen, Forman, Bolognia, and Kovarik have no conflicts of interest to declare.
| Reprints not available from the authors.